Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser
MWN-AI** Summary
On February 18, 2026, STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced that Johns Hopkins Dermatology has integrated the XTRAC® 308 nm excimer laser into its treatment offerings. This advanced technology significantly enhances the center's capability to provide targeted care for patients suffering from inflammatory and autoimmune skin conditions, among them psoriasis, vitiligo, and atopic dermatitis. The introduction of the XTRAC laser not only improves the clinical treatment landscape but also bolsters Johns Hopkins' ongoing research initiatives aimed at furthering academic advancements in dermatology.
Dr. Dolev Rafaeli, CEO of STRATA Skin Sciences, highlighted the essential role that academic medical centers play in enhancing patient outcomes and prioritizing evidence-based dermatologic care. Collaborating with leading institutions like Johns Hopkins underscores the importance of precision treatment strategies in managing inflammatory skin diseases, thereby expanding access to FDA-cleared phototherapy in these prestigious settings.
The addition of XTRAC at Johns Hopkins aligns with similar initiatives at various esteemed institutions across the U.S. and internationally, including New York University and the Cleveland Clinic, all of which have recognized the efficacy of excimer laser therapy through over 300 peer-reviewed clinical studies. STRATA Skin Sciences remains committed to fostering partnerships with top academic hospitals worldwide, aimed at promoting research, education, and access to sophisticated dermatologic technologies.
Overall, the introduction of the XTRAC excimer laser at Johns Hopkins signifies a pivotal advancement in providing advanced care for challenging skin conditions, with the potential to improve the quality of life for many patients. As STRATA grows its partnerships and continues to innovate in dermatologic treatment, the company reinforces its mission to deliver cutting-edge solutions in skin health management.
MWN-AI** Analysis
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has recently boosted its growth prospects with the addition of the XTRAC® excimer laser by Johns Hopkins Dermatology to its treatment offerings for chronic inflammatory and autoimmune skin diseases. This strategic move underscores the increasing recognition of phototherapy's effectiveness in managing complex dermatologic conditions like psoriasis and vitiligo.
For investors, this expansion of product applications within prestigious academic institutions is a signal of STRATA’s commitment to innovation and clinical efficacy, as the XTRAC technology is associated with over 300 peer-reviewed studies. The collaboration with such a respected medical entity not only validates STRATA’s technology but also increases its visibility within the dermatology community, potentially driving demand for its products.
The implications of this partnership extend beyond just immediate revenue opportunities. By positioning itself alongside top-tier institutions such as New York University and Cleveland Clinic, STRATA enhances its credibility as a leader in dermatologic treatments. These partnerships can provide access to valuable clinical insights that could foster further product development, ensuring that STRATA remains competitive in a rapidly evolving market.
Investors should monitor STRATA’s engagement with other academic institutions, as expanding its partnership network could lead to increased adoption of its technologies. The company’s unique fee-per-treatment model also stands out, potentially reducing the barriers for clinics to adopt the XTRAC system compared to traditional capital expenditure models.
Despite the positive indicators, it is essential for investors to remain cautious. Engaging with high-profile institutions brings scrutiny, and any clinical or operational setbacks could influence market perception and stock performance. Overall, STRATA's trajectory looks promising, but prudent investors should stay informed on regulatory developments and market dynamics that could impact performance in the dermatology sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatment offerings.
The addition of XTRAC enhances Johns Hopkins’ ability to deliver advanced, targeted care for patients living with chronic inflammatory and autoimmune skin diseases, including psoriasis, vitiligo, atopic dermatitis, and other complex dermatologic conditions. The technology will also support ongoing clinical research and academic initiatives within the department, reinforcing its commitment to evidence-based dermatologic innovation.
“Academic medical centers play a critical role in advancing evidence-based dermatologic care, an essential component to improving patient outcomes and quality of life,” said Dr. Dolev Rafaeli, Chief Executive Officer of STRATA Skin Sciences. “Collaboration with Johns Hopkins and other leading institutions that prioritize both clinical excellence and research innovation underscores the importance of precision treatment strategies in managing inflammatory skin disease while expanding access to targeted, FDA-cleared phototherapy in these prestigious centers. STRATA Skin Sciences remains committed to partnering with top academic institutions worldwide to support research, education, and access to advanced dermatologic technologies.”
Johns Hopkins joins a distinguished group of leading academic institutions across the United States and internationally that have integrated XTRAC into their clinical programs. Centers such as New York University, University of California, Cleveland Clinic, Cornell University, and many others recognize the demonstrated effectiveness and patient-centered benefits of excimer laser therapy in managing challenging inflammatory skin conditions.
Excimer laser technology treatment procedures are supported by more than 300 published peer-reviewed clinical studies. Partnerships with renowned academic hospitals like Johns Hopkins further advance the generation of clinical evidence supporting precision phototherapy strategies.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. More specific risks and uncertainties are set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ**
What strategic advantages does Strata Skin Sciences Inc. SSKN expect to gain from partnering with leading institutions like Johns Hopkins Dermatology for the XTRAC® laser treatment?
How does Strata Skin Sciences Inc. SSKN plan to leverage the 300 published clinical studies to enhance its product offerings and attract more partnerships in the dermatology field?
In what ways does Strata Skin Sciences Inc. SSKN intend to expand access to its excimer laser technology for treating chronic skin conditions, particularly through its Partnership Program?
What potential risks or uncertainties does Strata Skin Sciences Inc. SSKN foresee regarding its future growth and the evolution of the dermatologic market, as mentioned in their SEC reports?
**MWN-AI FAQ is based on asking OpenAI questions about Strata Skin Sciences Inc. (NASDAQ: SSKN).
NASDAQ: SSKN
SSKN Trading
-23.2% G/L:
$0.2208 Last:
1,743,206 Volume:
$0.2848 Open:
